의약품 CDMO 시장 : 서비스 유형별, 기술별, 치료 모달리티별, 최종 용도별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Pharmaceutical CDMO Market size was valued at US$ 180,418.09 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) is a specialized service provider that supports pharmaceutical and biotechnology companies in developing, producing, and commercializing drugs. CDMOs offer services spanning drug formulation, process development, clinical and commercial manufacturing, analytical testing, and packaging. By partnering with CDMOs, companies gain access to advanced technologies, regulatory expertise, and flexible production capacity, enabling faster time-to-market and cost efficiency. Beyond service provision, CDMOs act as strategic collaborators, particularly for complex therapies such as biologics and gene therapies, fostering innovation, quality compliance, and sustainable growth. Governments and global agencies such as the U.S. FDA, European Medicines Agency, and World Health Organization gradually emphasize domestic manufacturing resilience and quality standards, inspiring CDMO engagement to strengthen supply chains, support vaccine capacity, and align with public health objectives worldwide.

Pharmaceutical CDMO Market- Market Dynamics

Rising demand for advanced biologic therapies to support long-term healthcare sustainability

The rising demand for advanced biologic therapies is a key catalyst for growth in pharmaceutical manufacturing and outsourcing because these therapies, such as monoclonal antibodies, recombinant proteins, vaccines, and cell-based treatments, are increasingly used to treat complex chronic conditions, including cancer, autoimmune diseases, and metabolic disorders. Pharmaceutical companies are expanding their biologics portfolios to meet this need, and regulators in major markets are facilitating this evolution. For instance, the U.S. Food and Drug Administration (FDA) has been actively adapting guidance to accelerate development and access to biosimilars and advanced biologic drugs, helping increase availability while managing costs for patients.

In response to this sustained demand, leading global manufacturers are investing in capacity expansion and strategic assets. South Korea's Samsung Biologics is expanding its presence in the United States by acquiring a Maryland production facility to support biologics output and meet long term demand. On the policy side, countries like India have announced major programmes to bolster biopharmaceutical capabilities, including a dedicated ₹10,000 crore initiative over five years to position the nation as a global hub for biologics and biosimilars manufacturing. These combined public and private commitments reflect how biologic therapies are shaping sustainable healthcare priorities worldwide.

Pharmaceutical CDMO Market- Segmentation Analysis:

The Global Pharmaceutical CDMO Market is segmented on the basis of Service Type, Technology, Therapeutic Modality, End-Use, and Region.

Based on service type market is divided into five categories: Drug Development Services, Analytical and Regulatory Support, Clinical Manufacturing, Commercial Manufacturing, and Packaging & Serialization Services. Commercial Manufacturing act as a central role in the market because it delivers the large scale production capacity that sponsors most urgently need once drugs clear clinical development. Companies like Lonza have shown this segment's importance: in 2025, its core CDMO business - heavily weighted toward commercial manufacturing across small molecule and biologics platforms - grew to CHF 6.5 billion in sales, accounting for a substantial portion of overall revenue and driving expanded margins. Government continuous efforts, such as the U.S. FDA's PreCheck initiative, also reinforce the priority of scaling domestic manufacturing by streamlining facility reviews and enhancing production infrastructure, underscoring commercial manufacturing's pivotal role in supporting reliable supply and market access.

The market is divided into five categories based on therapeutic modality: Small Molecules, Biologic Molecules, Advanced Therapies, Vaccines, and Specialized Formulations. While Small Molecules remain widely used due to established manufacturing processes and lower complexity, Biologic Molecules are expected to play a key role in CDMO demand because they require advanced technologies, specialized facilities, and strict regulatory compliance. Unlike small molecules, biologics such as monoclonal antibodies, recombinant proteins, and cell-based therapies cannot be produced easily at scale in-house. Companies like Lonza and Samsung Biologics invest heavily in biologics manufacturing capacity, reflecting higher outsourcing reliance. Government initiatives, including the U.S. FDA's accelerated biologics approval programs, further reinforce the focus on biologics as a strategic priority in global pharmaceutical manufacturing.

Pharmaceutical CDMO Market- Geographical Insights

North America is expected to play a key role in the Pharmaceutical CDMO market, driven by continued investments from both the government and private sectors to enhance domestic drug production capabilities. The U.S. Food and Drug Administration (FDA) has launched programs such as the PreCheck Pilot Program, which aims to simplify regulatory approvals and expedite the development of new pharmaceutical manufacturing facilities across the United States. These efforts reduce dependence on imports, strengthen supply chain stability, and support the expansion of local manufacturing capacity, in line with national priorities to ensure reliable access to essential medicines.

In parallel, major pharmaceutical companies are increasing their North American manufacturing footprint. For example, Novartis plans to build a new radioligand therapy manufacturing site in Texas as part of a multi-facility expansion, while AbbVie is investing hundreds of millions of dollars to expand API manufacturing in Illinois, reflecting industry confidence in regional capabilities and government incentives for domestic production. These investments not only create employment but also demonstrate how public policy and corporate strategic planning are converging to position North America as a central hub for advanced pharmaceutical manufacturing and CDMO activities.

South Korea Pharmaceutical CDMO Market- Country Insights

South Korea has positioned itself as a significant contributor to the global Pharmaceutical CDMO ecosystem through targeted government support and dynamic industry advancement. The South Korean government has identified biopharmaceuticals as a strategic sector, including technologies for vaccines, mRNA, and protein production, among key national priorities to bolster long term growth and self-reliance. Regulatory authorities are also considering supportive legislation to formally enhance CDMO activities and export manufacturing frameworks, reflecting policy emphasis on pharmaceutical innovation and global supply chains.

At the corporate level, Samsung Biologics, headquartered in Songdo, Incheon, demonstrates South Korea's growing CDMO stature, with substantial manufacturing contracts with international partners and ongoing capacity expansions. The company reported revenues above 4.5 trillion Korean won in 2025 and has secured significant multi-year manufacturing agreements that underline demand for its biopharmaceutical services. Its strategic investments in additional plants and advanced biologics production platforms further reinforce South Korea's role as an emerging hub for biomanufacturing and contract development services.

Pharmaceutical CDMO Market- Competitive Landscape:

The Pharmaceutical CDMO market is highly competitive, comprising global leaders and specialized regional providers offering end-to-end drug development and manufacturing services. Companies compete based on technical expertise, regulatory compliance, manufacturing capacity, quality standards, and time-to-market efficiency. Leading players focus on expanding production facilities, investing in biologics and advanced therapy capabilities, and enhancing analytical and regulatory services. Strategic approaches such as mergers and acquisitions, long-term partnerships with pharmaceutical sponsors, new service launches, and geographic expansion are commonly employed to strengthen market presence. Firms like Lonza, Samsung Biologics, and Catalent exemplify these strategies, reinforcing their global leadership and client reach

Recent Developments:

In January 2026, Zydus completed the establishment of Zylidac Bio LLC, solidifying its U.S. biologics CDMO presence and aligning with regulatory trends supporting secure domestic manufacturing, thereby improving service availability for global biopharmaceutical partners.

In September 2025, Terumo Corporation acquired a drug product plant and quality control operations from WuXi Biologics in Leverkusen, Germany, enhancing its production scale and quality control capabilities for serving both local and international pharmaceutical customers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PHARMACEUTICAL CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• Catalent
• Thermo Fisher Scientific
• Lonza Group
• Recipharm AB
• Samsung Biologics
• WuXi AppTec
• Cambrex Corporation
• WuXi Biologics
• Piramal Pharma Solutions
• Corden Pharma International
• Vetter Pharma
• Eurofins CDMO
• Others

GLOBAL PHARMACEUTICAL CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

• Drug Development Services
• Analytical and Regulatory Support
• Clinical Manufacturing
• Commercial Manufacturing
• Packaging & Serialization Services

GLOBAL PHARMACEUTICAL CDMO MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

• Chemical Synthesis & API Manufacturing
• Fermentation & Bioprocessing
• Fill-Finish & Aseptic Processing
• Continuous Manufacturing
• Advanced Analytical Technologies

GLOBAL PHARMACEUTICAL CDMO MARKET, BY THERAPEUTIC MODALITY- MARKET ANALYSIS, 2019 - 2032

• Small Molecules
• Biologic Molecules
• Advanced Therapies (Cell, Gene, and Tissue)
• Vaccines
• Specialized Formulations (e.g., liposomal, nanoparticle)

GLOBAL PHARMACEUTICAL CDMO MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

• Large Pharmaceutical Companies
• Mid-Size Biotech Firms
• Virtual Pharma
• Public Health Programs
• Non-Profit Research Consortia

GLOBAL PHARMACEUTICAL CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Pharmaceutical CDMO Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Pharmaceutical CDMO Market Snippet by Service Type
  • 2.1.2. Pharmaceutical CDMO Market Snippet by Technology
  • 2.1.3. Pharmaceutical CDMO Market Snippet by Therapeutic Modality
  • 2.1.4. Pharmaceutical CDMO Market Snippet by End-Use
  • 2.1.5. Pharmaceutical CDMO Market Snippet by Country
  • 2.1.6. Pharmaceutical CDMO Market Snippet by Region
• 2.2. Competitive Insights

3. Pharmaceutical CDMO Key Market Trends

• 3.1. Pharmaceutical CDMO Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Pharmaceutical CDMO Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Pharmaceutical CDMO Market Opportunities
• 3.4. Pharmaceutical CDMO Market Future Trends

4. Pharmaceutical CDMO Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Pharmaceutical CDMO Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Pharmaceutical CDMO Market Landscape

• 6.1. Pharmaceutical CDMO Market Share Analysis, 2024
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Pharmaceutical CDMO Market - By Service Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
  • 7.1.2. Drug Development Services
  • 7.1.3. Analytical and Regulatory Support
  • 7.1.4. Clinical Manufacturing
  • 7.1.5. Commercial Manufacturing
  • 7.1.6. Packaging & Serialization Services

8. Pharmaceutical CDMO Market - By Technology

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
  • 8.1.2. Chemical Synthesis & API Manufacturing
  • 8.1.3. Fermentation & Bioprocessing
  • 8.1.4. Fill Finish & Aseptic Processing
  • 8.1.5. Continuous Manufacturing
  • 8.1.6. Advanced Analytical Technologies

9. Pharmaceutical CDMO Market - By Therapeutic Modality

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Therapeutic Modality, 2024 & 2032 (%)
  • 9.1.2. Small Molecules
  • 9.1.3. Biologic Molecules
  • 9.1.4. Advanced Therapies (Cell, Gene, and Tissue)
  • 9.1.5. Vaccines
  • 9.1.6. Specialized Formulations (e.g., liposomal, nanoparticle)

10. Pharmaceutical CDMO Market - By End-Use

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
  • 10.1.2. Large Pharmaceutical Companies
  • 10.1.3. Mid Size Biotech Firms
  • 10.1.4. Virtual Pharma
  • 10.1.5. Public Health Programs
  • 10.1.6. Non Profit Research Consortia

11. Pharmaceutical CDMO Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Pharmaceutical CDMO Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Pharmaceutical CDMO Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.9. UK
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.9.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.9.4. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.9.5. UK Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.9.6. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.10. France
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.10.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.10.4. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.10.5. France Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.10.6. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.11. Italy
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.11.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.11.4. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.11.5. Italy Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.11.6. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.12. Spain
    • 11.3.12.1. Overview
    • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.12.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.12.4. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.12.5. Spain Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.12.6. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.13. The Netherlands
    • 11.3.13.1. Overview
    • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.13.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.13.4. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.13.6. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Overview
    • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.14.6. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.15. Russia
    • 11.3.15.1. Overview
    • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.15.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.15.4. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.15.5. Russia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.15.6. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.16. Poland
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.16.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.16.4. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.16.5. Poland Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.16.6. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3.17. Rest of Europe
    • 11.3.17.1. Overview
    • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Pharmaceutical CDMO Key Manufacturers in Asia Pacific
  • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 11.4.5. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.4.6. APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
  • 11.4.7. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.8. China
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.8.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.8.4. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.8.5. China Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.8.6. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.9. India
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.9.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.9.4. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.9.5. India Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.9.6. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.13. Indonesia
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.13.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.13.4. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.13.6. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.14. Thailand
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.14.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.14.4. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.14.6. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
• 11.5. Latin America (LATAM)
  • 11.5.1. Overview
  • 11.5.2. Pharmaceutical CDMO Key Manufacturers in Latin America
  • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 11.5.5. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.5.6. LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
  • 11.5.7. LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
• 11.6. Middle East and Africa (MEA)
  • 11.6.1. Overview
  • 11.6.2. Pharmaceutical CDMO Key Manufacturers in Middle East and Africa
  • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  • 11.6.5. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.6.6. MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
  • 11.6.7. MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Pharmaceutical CDMO Industry

• 12.1. Competitive Benchmarking
  • 12.1.1. Competitive Dashboard
  • 12.1.2. Competitive Positioning
• 12.2. Company Profiles
  • 12.2.1. Catalent
  • 12.2.2. Thermo Fisher Scientific
  • 12.2.3. Lonza Group
  • 12.2.4. Recipharm AB
  • 12.2.5. Samsung Biologics
  • 12.2.6. WuXi AppTec
  • 12.2.7. Cambrex Corporation
  • 12.2.8. WuXi Biologics
  • 12.2.9. Piramal Pharma Solutions
  • 12.2.10. Corden Pharma International
  • 12.2.11. Vetter Pharma
  • 12.2.12. Eurofins CDMO
  • 12.2.13. Others

13. 360 Degree AnalystView

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us